How Zera Health works, what it costs, and where its public pages conflict
This review deliberately covers only AllyRx-relevant care: GLP-1 weight management, testosterone context, longevity compounds, sexual health, hair loss, and hormone context. General wellness marketing and unrelated services do not expand the scope.
Zera Health says it is a technology platform rather than a medical provider. Its medical consent says an independent licensed provider reviews the intake and may prescribe when appropriate. The public pages reviewed do not identify the operating company or medical group.
The provider page describes physicians, nurse practitioners, and physician assistants and lists credentialing standards, but it does not name the chief medical officer or individual clinicians. A patient is told the assigned provider's identity will appear in the portal after consultation.
One refund policy says compounded medications are dispensed by Strive Pharmacy and coordinated through TelegraMD. The footer likewise names Strive. A separate transparency page says Zera uses multiple accredited state-licensed pharmacies and gives the patient-specific pharmacy later. Those statements are not reconciled.
The home page and FAQ use all-inclusive language: a flat monthly rate includes provider consultation, prescription, and free shipping, with no separate membership. A second refund policy says a plan may include medication, labs, consultations, care coordination, and support, and that inclusion varies by plan.
Injectable semaglutide publishes $179 monthly and $149 per month when billed every three months. Their unweighted mean is $164 per month. The separate $149 first-month headline is promotional and is not mixed into the recurring average.
Injectable tirzepatide publishes $255 monthly and $215 per month when billed every three months. Their unweighted mean is $235 per month. The $199 first-month headline remains a promotion rather than an ongoing comparison price.
The home page lists a compounded oral GLP-1 tablet from $169 per month. Its dedicated page calls the product oral but repeats the injectable semaglutide 2.5 mg or 5 mg vial block at $179 or $149 per month. The card therefore uses only the short from-price and stays comparison-disabled.
Brand Wegovy, Ozempic, Mounjaro, and Zepbound listings do not publish dependable medication totals. They are consolidated by ingredient and route in editorial context, not counted as extra therapies or averaged into the compounded-product cards.
Microdose GLP-1 is not given a stable active ingredient on the reviewed page. Its product page also repeats the semaglutide vial template. It remains editorial-only rather than becoming an ingredient-level card.
The transparency page lists testosterone cypionate or enanthate injections and compounded testosterone cream or gel. The dedicated TRT URL currently redirects to the home page, and no public ongoing price, exact ester selection, route, strength, quantity, lab schedule, or state list is established.
Sermorelin injection and sermorelin orally dissolving tablets each show $155 monthly and $130 per month on a quarterly plan, producing a compact unweighted average of $142.50, displayed as Avg. $143/mo. These are two route-specific cards, not two distinct active ingredients.
NAD+ injection and NAD+ nasal spray each publish $130 monthly and $110 per month on a quarterly plan, so both display Avg. $120/mo. Exact directions and evidence for marketed energy, cognition, DNA-repair, and longevity outcomes require clinician review.
Glutathione nasal spray publishes $124 monthly and $99 per month on a quarterly plan, averaging $111.50 and displaying Avg. $112/mo. The injectable glutathione URL redirects to the home page and does not become another card.
MIC plus B12 publishes $95 monthly and $79 per month on a quarterly plan, averaging $87/mo. It remains one multi-ingredient provider-product card because exact component concentrations are not public.
The transparency page labels Daily Wellness coming soon even though dedicated NAD+, sermorelin, glutathione nasal, and MIC plus B12 pages are live with intake links and prices. Availability must be confirmed before payment.
Sildenafil and tadalafil each show a $49 first-month headline, while the recurring plan block describes a 2.5 mg or 5 mg vial and repeats the same $179 or $149 template seen on unrelated pages. Only the promotional first-month amount is retained, and no ongoing monthly price is invented.
Trimix is described as a compounded three-ingredient injection, but the ingredient names, concentrations, vial quantity, and valid recurring price are not published. It stays editorial-only.
Finasteride is described as an oral hair-loss product and shows a $39 first month. Oral minoxidil shows a $49 first month. Both pages then repeat semaglutide questions and the unrelated vial price block, so no ongoing monthly total is used.
Rogaine is consolidated as topical minoxidil rather than counted as a separate medication. Propecia is consolidated under oral finasteride. A finasteride plus minoxidil combination remains editorial-only because route, strengths, quantity, and recurring price are unresolved.
The women's-health page labels hormone therapy, fertility, skin, and hair programs coming soon, while the home page markets HRT or estradiol in cream, patch, or oral forms from $69 per month. The status, exact active ingredients, routes, quantities, and recurring terms conflict, so HRT remains editorial-only.
FDA explains that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. FDA also warns telehealth marketers not to imply that a pharmacy is FDA approved or that a compounded drug is the same as an approved product.
Zera's footer correctly says compounded medications are not FDA approved but repeatedly describes Strive or other pharmacies as FDA-regulated. Pharmacy licensing or regulation does not make an individual compounded product FDA approved.
FDA's current GLP-1 policy limits routine compounding copies after semaglutide and tirzepatide shortage conditions stabilized. A prescriber and pharmacy must establish a lawful patient-specific basis; a broad catalog listing alone does not do that.
FDA has separately reported dosing errors with compounded semaglutide vials and concerns involving ingredients used in sterile NAD+ compounding. Patients should verify the exact formula, concentration, syringe units, storage, pharmacy, and instructions on the dispensed label.
The site makes strong claims about NAD+ and glutathione brain delivery, rapid onset, bioavailability, cellular repair, longevity, and safety without linking evidence on the pages. The review treats them as provider marketing, not established patient outcomes.
Oral minoxidil is FDA labeled for severe hypertension, not hair loss. Hair-loss use is off-label and requires individual cardiovascular assessment and monitoring. A generic telehealth intake does not establish suitability.
The FAQ says compounded GLP-1 medicines are legal when approved products are unavailable or cost-prohibitive. Cost alone does not establish every federal compounding condition, so this review does not repeat that as a blanket legal conclusion.
The public home page says Zera operates in all 50 states. The FAQ says most states, the transparency page says consultation mode depends on state law, and product availability is treatment-specific. No card promises nationwide availability.
Fulfillment timing ranges from shipping in 48 hours, shipping in 48 to 72 hours, delivery in 3 to 5 business days, delivery in 3 to 7 business days, and first shipment in 5 to 7 business days. All are provider estimates rather than one guaranteed SLA.
Cancellation terms conflict. The April 1 page provides a seven-day initial-purchase refund only before provider review or prescribing. The May 20 page requires 72 hours before renewal and generally provides no cancellation refund except medical disqualification. Use the stricter cutoff and seek written confirmation.
The footer's Terms link currently opens SMS Terms of Service rather than a complete platform Terms of Use, even though other legal pages refer to governing terms and binding arbitration in Miami. This leaves core contract, dispute, and entity disclosures incomplete.
A Notice of Privacy Practices lists collection of identity, health, payment, device, and usage data and says Stripe processes cards. The Privacy Policy redirects to that notice. It is not a substitute for confirming which entity is a HIPAA covered entity or business associate.
Awin advertiser 127175 is still pending in AllyRx's affiliate record. The commission is undisclosed, attribution is 30 days, and no tracking URL or customer promotion is approved. Commercial status does not affect the 53/100 editorial score.
- Sixteen cards cover defensible ingredient-and-route records; brand names and promotional variants do not inflate the count.
- Eight products use compact averages of their public monthly and quarterly equivalents.
- Copied 2.5 mg or 5 mg vial pricing is excluded from oral, ED, and hair-loss cards.
- The operator, medical group, and individual public clinician roster are not identified.
- Two cancellation pages disagree on notice and refund eligibility.
- State, pharmacy, availability, support-hour, and delivery statements conflict.
- The public Terms link serves SMS terms rather than complete platform terms.
- FDA distinctions qualify compounded GLP-1, NAD+, and other compounded-product claims.
- Affiliate approval, tracking URL, and customer promotion are all still pending.